Legend Capital Portfolio Company Giant Biogene Successfully Lists on the HKEX
HONG KONG, Nov 07, 2022 - (ACN Newswire) - On November 4, 2022, Legend Capital portfolio company Giant Biogene (2367.HK) was successfully listed on the main board of the Hong Kong Stock Exchange. The number of Giant Biogene's offer shares under the global offering is 22,608,800 shares at an issue price of HK$24.3 per share, which includes 2,261,200 Hong Kong offering shares, 20,347,600 international offering shares, as well as a 15% over-allotment option.
Giant Biogene is a leader in the bioactive ingredient-based professional skin treatment product industry in China and the first company in the world to successfully develop and industrialize recombinant collagen skin treatment products. Giant Biogene has been the largest collagen-based professional skin treatment product company by retail sales in China for the latest three consecutive years since 2019. According to Frost & Sullivan, Giant Biogene was the second-largest professional skin treatment product company in China in 2021, and its Collgene and Comfy, the flagship brands of recombinant collagen-based products, were the third and the fourth best-selling professional skin treatment brands, respectively. Giant Biogene is the first company to obtain a medical device registration for recombinant collagen-based products in China.
Legend Capital participated in Giant Biogene's only round of financing in 2021. Following the investment, Legend Capital provided Giant Biogene value-added services on core issues such as business strategy discussion, upstream and downstream business resource docking, executive talent introduction, and IPO listing process.
Richard LI, President of Legend Capital, said: "Congratulations to Giant Biogene on its successful listing on the main board of the Hong Kong Stock Exchange. Legend Capital is very honored to be an investor in Giant Biogene and to carry out in-depth investment cooperation with the company. With 22 years of development and unremitting efforts under the leadership of the company's management, Giant Biogene has achieved excellent results and has become a pioneer enterprise in the field of biosynthetic materials and products in China. We hope that Giant Biogene will make steady progress and achieve greater achievements in the future development and continue to brave the wind and the waves in the changing market."
Tony WANG, Managing Director of Legend Capital, said: "Giant Biogene is a pioneer in the synthetic biology industry. It not only builds a leading technology platform for genetic engineering, tissue engineering and material engineering but also applies scientific research results to the field of healthcare. Giant Biogene demonstrated the best practice out of the combination of production, education and research. We look forward to this diligent and pragmatic team continuing to go forward and leading Chinese brands to the international market in the future."
About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.
Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital).
Source: Legend Capital Sectors: BioTech, Healthcare & Pharm, PE, VC & Alternatives
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 Mitsubishi Motors to Launch an All-New BEV Based on Nissan's Next-Generation LEAF in North America in the Second Half of 2026 May 08, 2025 11:25 JST
|  Mitsubishi Motors and Foxtron Sign MOU for OEM Supply of EV May 08, 2025 11:08 JST
|  Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China May 07, 2025 19:06 JST
|  Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition May 03, 2025 03:00 JST
|  TOYOTA GAZOO Racing Set for Spa spectacle May 02, 2025 19:29 JST
|  FWD Group reports exceptionally strong first quarter new business update May 02, 2025 17:00 JST
|  Toyota Mobility Foundation, Bangkok Metropolitan Administration, UN-Habitat, Asian Institute of Technology and Toyota Motor Thailand Sign a Letter of Intent (LOI) to Launch the TRUST Project for Road Safety in Thailand May 01, 2025 17:48 JST
|  Katalon Officially Launches TrueTest(TM) - The First AI-Native Testing System That Thinks Like a Tester and Learns from Users Apr 30, 2025 17:20 JST
|  Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star Apr 30, 2025 14:17 JST
|  Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of Large Car Ferry KEYAKI in Shimonoseki Apr 29, 2025 17:24 JST
|  NEC DGDF Headquarters relocates to Zurich to accelerate growth and enhance management globally Apr 28, 2025 16:03 JST
| NEC achieves Japan's longest terrestrial wireless optical communication over 10 km Apr 25, 2025 17:50 JST
|  Olympus Appoints New CEO Apr 25, 2025 15:30 JST
|  DENSO Announces Year-End Financial Results Apr 25, 2025 12:17 JST
|  DENSO and DELPHY Sign Memorandum of Understanding to Develop Data-Driven Smart Horticulture Apr 24, 2025 18:43 JST
|  MyJCB App Wins "iF DESIGN AWARD 2025" Apr 24, 2025 17:00 JST
|  Fujitsu launches new company 1FINITY to strengthen network products business
Apr 24, 2025 16:24 JST
|  MHIEC Completes Renovation of Core Facilities for Arita Municipal Recycle Plaza in Saga Prefecture Apr 24, 2025 15:01 JST
|  NEC invests in U.S.-based "Geodesic Alliance Fund" aiming to strengthen economic security business Apr 24, 2025 10:23 JST
|  MHI Thermal Systems Wins German Red Dot Design Award 2025 Apr 24, 2025 10:11 JST
|
More Latest Release >>
|